Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 466

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 9A
Chunk 466
---
 recorded $20.6 million, $22.0 million and $53.2 million of interest expense, respectively. Total interest expense for the years ended December 31, 2024, 2023 and 2022 is inclusive of $5.0 million, $5.2 million and $7.5 million of amortization of debt discounts, respectively. The fair values of the 2027 Notes and 2024 Notes are based on open market trades and are classified as Level 1 in the fair value hierarchy. The following table summarizes the total principal and contractual interest payments due under the Company’s debt arrangements:

        As of December 31, 2024

        Principal

        Interest

        Total Payments

        (in thousands)

        2025
         
        $
        —

        $
        14,375

        $
        14,375

        2026

        —

        14,375

        14,375

        2027

        1,150,000

        14,375

        1,164,375

        Total payments
         
        $
        1,150,000

        $
        43,125

        $
        1,193,125

F-29

14. EQUITY In November 2024, the Board of Directors approved a share repurchase program (the “2024 Repurchase Program”) of up to $500.0 million of the Company’s outstanding common stock over the next 18 months. Correspondingly, the Company entered into a Rule 10b-18 repurchase plan that allows it to conduct open market repurchases periodically up to the remaining authorization under the 2024 Repurchase Program. There were no share repurchases of our common stock during the year ended December 31, 2024.Repurchased shares are held as treasury stock. The amount paid to repurchase shares will be recorded as a reduction to stockholders’ equity. As treasury stock is not considered shares outstanding, it will be excluded from average common stock outstanding for both basic and diluted earnings per share. 

15. STOCK-BASED COMPENSATIONIn June 2013, the Company’s stockholders approved the 2013 Employee Stock Purchase Plan (the “2013 ESPP”) which authorized 0.3 million shares of common stock available to be issued. In June 2016, 2019 and 2023, the Company’s stockholders approved an additional 0